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Understanding drug transportation mechanisms in the human body is of paramount
importance in modeling Pharmacokinetic-Pharmacodynamic relationships. This work
gives a novel general model of efavirenz transportation projections based on
concentrations simulated from patients on a dose of 600mg. The work puts forward
a proposition that transportation can wholly be modeled by concentration and time in a
uniform volumetric space. Furthermore, movement entities are used to inform the state
of “kinetic solubility” of a solution. There is use of Ricker’s model, and forms of the Hill’s
equation in modeling transportation. Characterization on the movement rates of solution
particle are suggested in relation to advection rate of solution particle. At turning points
on the transportation rate of solution particle vs. concentration curve, a suggestion of
possibly change of dominance in the mode of transportation and saturation is made.
There are four movement rates postulated at primary micro-level transportation, that are
attributed to convection, diffusion [passive transportation ( EI)] and energy dependent
system transportation ( ED) in relation to advection. Furthermore, a new parameter is
introduced which is defined as an advection rate constant of solution particle. It is
postulated to be dependent on two rate constants of solution particle, that is a convection
rate constant of solution particle and a saturable transportation rate constant of solution
particle. At secondary micro-level transportation, the results show convection as sum
of advection and saturable transportation. The kinetics of dissolution of efavirenz in the
solution space is postulated. Relatively, a good level of kinetics of dissolution is projected
in the concentration region 0− 32.82µg/ml.
Keywords: efavirenz, models, advection rate, passive transportation and energy dependent transportation rate,
convection rate, advection rate constant, kinetic solubility
1. Introduction
Efavirenz is an antiviral drug that has low solubility and high permeability
(pKa = 10.2 and log P = 5.4) (Pinto et al., 2014). Efavirenz has been
recommended as the preferred option for a non-nucleoside reverse transcriptase
inhibitor in optimized first-line antiretroviral regimens (WHO, 2012; Ford et al.,
2014). Efavirenz is a drug that exhibit low and variable oral bioavailability.
Nemaura Modeling transportation of efavirenz
Relationships of dissolution to bioavailability has been suggested
(Dokoumetzidis and Macheras, 2006).
Modeling transportation has been mainly done using location
and time space variables. The use of partial differential equations
continues to be used in modeling diffusion patterns. Ogata and
Banks (1961) derived the analytical solution to the advection-
dispersion equation. Stochastic differential equations are also
in use in modeling diffusion patterns, this has had extensions
in areas of mathematics that include population dynamics and
financial mathematics (Øksendal, 2000).
In the transportation of a drug there were inferences on the
different possible transportation modes acting on the drug in
the volumetric space. A solution particle in this work, is a zero
sum movement entity for any given concentration consisting of
movements due to concentration and the system’s environment.
It has equal pro-solvation and anti-solvation movement entities
at any given concentration. Furthermore, it is the smallest particle
of a solution. In this work mathematical models with biological
implications are suggested. There are new parameters developed
for the movement rates of solution particle. Furthermore, a
proposition of an identification of the advection rate of solution
particle parameter is given.
The Hill’s equation was introduced by A. V. Hill to describe
the relationship between oxygen tension and the saturation of
hemoglobin a static effect (Goutelle et al., 2008). In this work
it is used to describe saturation dissolution transportation in
relation to concentrations of efavirenz. Additionally, the Ricker’s
model is used tomodel convection transportation rate of solution
particle. This model has had applications in fishery, biological
sciences, and population modeling in the description of “growth”
rates in conditions where there is mortality and recruitment (Paz
and Larraneta, 1992; Nelis, 2012; Wieland and Siegstad, 2012).
When concentration was increasing in the volumetric space, the
collective aggregated movement (convection) was expected to
initially increase and then decrease. This was postulated to be
mainly so, because of the finite volumetric space, elimination and
uptake of the drug, amongst other factors that could potentially
affect the convection rate as concentration increased.
The Michaelis-Menten equation is a special example of
the Hill’s equation and describes the relationship between the
velocity of the reaction (dynamic effect) and the concentration
of the substrate (Goutelle et al., 2008). It also describes
non-linear saturation relationships. An energy dependent
system transportation rate of solution particle is modeled
by the Michaelis-Menten equation. The energy independent
transportation rate of solution particle is modeled by the
“inverse” Michaelis-Menten equation. This includes all forms
of possible passive transportation rates of solution particle in
the movement of a drug (efavirenz) in the volumetric space
(Volume of Distribution) (Peck et al., 2008). The Michaelis-
Menten equation is used because of saturation that was
expected in transportation. As concentration increased in the
systemic circulation there was an expected reduction in the rate
due to dependency on concentration gradient for the passive
transportation rate of solution particle.
The work made use of properties at the point associated with
full absorption to help infer the possible transportation of the
drug efavirenz for differing efavirenz plasma concentration with
the aid of mathematical models. This work was motivated by the
notion of attempting to find models with physiological rationale
in the transportation of the drug efavirenz (Ette and Williams,
2007). Understanding transportation could also possibly help in
explaining mechanisms that contribute to CNS side effects in the
use of drugs (Nigam, 2015).
2. Materials and Methods
Simulations were developed from 61 patients who had been
on efavirenz containing HAART, this work made use of model
2b(i), Equations (1.4) and (1.10) in Nemaura (2014). The R
Statistical package was used to further develop models in this
work. There is use of the non-linear regression models in
curve fitting. Furthermore, the following models were used,
Ricker’s Model, Michealis-Menten equation and the Hill’s
equation.
3. Results
An estimation of the behavior of the differing concentrations
in the volumetric space was made at the point associated with
full absorption. The point associated with full absorption was
observed to be important and unique where xu(t) ≈ x(t) since the
uptake-volume(V)
volume of distribution(Vd)
≈ 1 (xu(t) =
A
V(1− ke)
(e−ket−e−t)
was taken as a function that defined full mass transfer of the drug,
A was the absolute bioavailability, ke elimination rate constant
and V = 35.56L was the uptake-volume (transportation volume)
associated with full absorption, and x(t) was concentration at
time t). A proposition on an equilibrium state in transportation
was made at this point and captured by the transport equation
(Equation 1.10) in Nemaura (2014), which could be written as
ke = −
1
γ
(
D
V
−
A
V
)
(1)
where D = 600mg was the dose given. The factor − 1
γ
represents transport rate into the opposing system. It was
identified as the movement rate generated by the bulk movement
of transportation volume containing efavirenz projected, and
with the units ml
µg.h
. The left side of Equation (1) represents a
system which is only related to what had presumably reached the
systemic circulation. The right side represents the complement.
An assumption of equality of this rate to the system that empties
into the systemic circulation at the point of full absorption was
made. This was because of zero net flow of the drug in both
systems that is the systemic system (that assimilated A) and its
complement (that assimilatedD−A). This point was regarded as
an equilibrium point with respect to net flow.
3.1. Advection Rate, Convection Rate, and ED
and EI Transportation Rates
The movement rates of solution particle in this section describe
the primary micro-level transportation system. The volumetric
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TABLE 1 | Parameter estimates in modeling movement rates in
Equation (2).
Parameters Estimate Std Error t-value Pr(> |t|)
n −0.0561 0.0057 −9.764 5.18×10−10
b 7.4315 0.6922 10.737 7.49×10−11
g 0.0089 0.0003 32.289 < 2× 10−16
h 0.0598 0.0015 39.930 < 2× 10−16
p 0.8808 0.0874 10.076 2.75×10−10
m 0.0034 0.0002 14.010 2.43×10−13
system was assumed to be homogeneous and transportation to
be uniform for similar concentrations across individuals. This
was due to possibilities of overlapping in substrate specificities
among drug transporters and compensatory up-regulation of
other drug transporters as a result of loss of the other (Nigam,
2015). Additionally, an assumption of instantaneous spread in
the volumetric space was made. An assumption that advection at
a macro-level as described above equals one at a micro-level thus,
the advection rate of solution particle (inherent solution particle
movement due to anti-solvation/anti-dissolutionmovement) was
also given by− 1
γ
and the following highly statistically significant
non-linear regression fit between x(x ∈ (0, 15.5]) and y was
obtained as (Equation 2 and Table 1),
y = −
1
γ
= gxe−hx︸ ︷︷ ︸
I
+
II︷ ︸︸ ︷
nx
b+ x
+m
(p
x
+ 1
)
︸ ︷︷ ︸
III
(2)
where
n−maximum energy dependent (ED) system transportation rate
of solution particle,
b−concentration at which ED transportation rate of solution
particle was half of n,
m−minimum energy independent (EI) transportation rate of
solution particle,
p−concentration at which EI transportation rate of solution
particle was twice ofm,
g−residence rate of the convection rate of solution particle,
h−declining rate of the convection rate of solution particle with
increasing concentration.
In Equation (2), part I− modeled convection rate of solution
particle (inherent solution particle movement due to pro-
solvation movement), part II− modeled the energy dependent
system transport rate of solution particle, and part III−modeled
passive transportation rate of solution particle.
As x → ∞ (as x gets large), II → n, III → m, and I → 0.
For large values of concentration, the convection rate of solution
particle was projected to be low in the volumetric space.
There were two turning points (Figure 1) one with the
least advection rate of 0.0082 ml
µg.h
(minimum)at a concentration
of 1.44µg/ml. The maximum advection rate was observed
at concentration of 12.5µg/ml. At x¯ = 0.97µg/ml the
passive transport rate equated to the energy dependent system
FIGURE 1 | The model fit of advection rate y against concentration x.
transportation rate. The equations that described the dominance
of either energy dependent or energy independent system
transportation were considered.


VTII(x) > VTIII(x), x > 0.97µg/ml case(i)
VTII(x¯) = VTIII(x¯), x = x¯ = 0.97µg/ml case(ii)
VTII(x) < VTIII(x), x < 0.97µg/ml case(iii)
(3)
where VTII, and VTIII were absolute values of II and III in
Equation (2). Considering Equation(s) (3) above it was deduced
that for case (i) energy dependent system transportation rate
of solution particle was dominating passive transportation since
the magnitude of part II was greater than the magnitude of
part III. The third case highlighted conditions where passive
transportation rate of solution particle was dominating energy
dependent system transportation rate of solution particle.
3.2. Transportation/Movement Rate Constants
and Kinetics of Dissolution of Solution Particle
Movement rate constants of solution particle are secondary
micro-level transportation measures. There was consideration of
the relationship between the proposed advection rate constant
of solution particle, convection rate constant of solution particle
and saturable transportation rate constant of solution particle
to the concentration of efavirenz in the volumetric system. The
advection rate constant of solution particle (ar) is defined as
the product of advection rate of solution particle and relative
uptake at the point of full absorption and is given by − A
γV . The
following highly statistically significant non-linear regression fit
between x(x ∈ (0, 15.5]) and ar(x) was obtained (Equation 4 and
Table 2)
ar: = −
A
γV
= ζxe−λx︸ ︷︷ ︸
q
+
s︷ ︸︸ ︷
αxω
ηω + xω
(4)
where
ζ−residence rate of the convection rate constant of solution
particle,
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λ−declining rate of the convection rate constant of solution
particle with increasing concentration,
α−maximum saturable transportation rate constant of solution
particle,
ω−Hill’s coefficient and
η−concentration at which the saturable transportation rate
constant of solution particle was half of α.
Considering Equation (4), qmodeled convection rate constant
of solution particle and s modeled saturable transportation rate
constant of solution particle. Furthermore, the following were
defined, q : = cr(x) and s : = −str(x) where cr(x) was the
convection rate constant of solution particle and str(x) was the
saturable rate constant of solution particle.
Since α was found being negative (Table 2 and Equation
4) it was noted that ar + str = cr . As x → ∞ (as
x gets large), ar(x) → −str(x) [and cr(x) → 0]. The
movement rate constants of solution particle are bounded.
The model (Equation 4 and Figure 2) thus showed that for
large values of x, increasing efavirenz concentration decreases
the convection rate constant of solution particle. Additionally,
with increasing advection shows similar characterization to
saturable transportation but in the opposite direction. This
results in the convection approaching zero, thus implying less
movement of the drug in the volumetric space at relatively high
concentrations.
The saturable transportation rate constant of solution particle
was shown to dominate the advection rate constant of solution
particle (Figure 2). Extrapolations (Figure 2) based on the
Equation (4) which were produced for the investigated range
of 0 − 15.5µg/ml showed possibilities of negative advection
rate constant of solution particle after xAd = 32.82µg/ml.
The extrapolation is observed when there was extension for
all the values of concentration. Beyond this concentration
value xAd , efavirenz is postulated to have increasingly poor
kinetic solubility. Kinetic solubility of solution particle, is
the equilibrium movement solubility entity that constitute
advection, saturation, and convection movements, of the
dissolved or precipitated solution particle at secondary micro-
level transportation for a given concentration and in a constant
homogenous solution systems environment.
The following phases are postulated in relation to kinetics of
dissolution and solubility of efavirenz. Initially, there are three
important kinetics of dissolution boundary points defined.
1. The rest/zero kinetics of dissolution boundary point x0(x0 =
0) which is such that all movement entities are zero.
TABLE 2 | Parameter estimates in modeling movement rate constants of
solution particle for Equation (4).
Parameters Estimate Std Error t-value Pr(> |t|)
ζ 0.1440 0.0040 35.69 < 2× 10−16
λ 0.0596 0.0007 79.89 < 2× 10−16
α −0.7427 0.0555 −13.38 3.59× 10−13
ω 1.1477 0.0123 92.98 < 2× 10−16
κ = ηω 6.071 0.2638 23.02 < 2× 10−16
2. The central kinetics of dissolution boundary point xAd (xAd >
0) which is such that ar(xAd ) = 0 and cr(xAd ) = str(xAd ) > 0.
3. The optimum kinetics of dissolution boundary point xC(xC >
xAd > 0) which is such that cr(xC) = 0 and −ar(xC) =
str(xC) > 0.
Three phases bounded by these kinetics of dissolution boundary
points are proposed below
• Kinetics of Dissolution Phase I (RI): Good Kinetics of
Dissolution
RI = {x ∈ (0, xAd ) : ar(x) > 0 and 0 < str(x) < cr(x)}
1. The concentration x is in a very kinetic soluble region of RI if
for ǫ1 > 0, x ∈ Nǫ1 (0).
2. The concentration x is in a freely kinetic soluble region of RI
if for ǫ1, ǫ2 > 0, x ∈ [ǫ1, xAd − ǫ2].
3. The concentration x is in a kinetic soluble region of RI if
ǫ2 > 0, x ∈ Nǫ2 (xAd ).
• Kinetics of Dissolution Phase II (RII): Poor Kinetics of
Dissolution
RII = {x ∈ (xAd , xC) : ar(x) < 0 and 0 < cr(x) < str(x)}
1. The concentration x is in a sparingly kinetic soluble region of
RII if for ǫ3 > 0, x ∈ Nǫ3 (xAd ).
2. The concentration x is in a slightly kinetic soluble region of RII
if for ǫ3, ǫ4 > 0, x ∈ [xAd + ǫ3, xC − ǫ4].
3. The concentration x is in a very slightly kinetic soluble region
of RII if for ǫ4 > 0, x ∈ Nǫ4 (xC).
• Kinetics of Dissolution Phase III (RIII): Undefined Kinetics
of Dissolution(Insolubility)
RIII = {x > xC : cr(x) = 0, ar(x) < 0 and str(x) = −ar(x)}
FIGURE 2 | The projected points (produced from Equation 4) of
efavirenz plasma concentration (x) in the range 0− 60µg/ml vs. rate
constants of solution particle [advection rate constant of solution
particle (ar ), convection rate constant of solution particle (cr ), and
saturable transportation rate constant of solution particle (absolute
(str ))].
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At concentration x = xC the system has reached saturation
and there is insolubility beyond this point. The volumetric
solution space can “no longer” support solvation. The system
has reached an “optimum dissolution capacity.” It should be
noted that str(x) = str(xC),∀x > xC (for every concentration
above xC). Furthermore, the models show that a solution
particle that is in the defined kinetics of dissolution region
remains in this region as long as the pro-solvation movement
of the solution particle can be accounted for however small. In
otherwords, it continues to dissolve as concentration increases
though with great difficulty. However, in reality when one can
no longer account for pro-solvation at secondary micro-level
of transportation (pro-solvation movement is very small/in the
neighborhood of zero) an adoption of undefined dissolution
kinetics (“no longer” dissolves) is made.
ǫ1, ǫ2, ǫ3, and ǫ4 are “small” radii of neighborhoods of
kinetics of dissolution boundary points. The neighborhoods are
pairwise disjoint, that is they describe different regions of kinetic
solubility. Kinetic solubility is relative to concentration and
solution system environment.
3.3. Acceleration Rate Constant of Convection
The convection movement was tracked using the convection rate
constants of solution particle projected using differing values of
concentration for the patient who was projected as having the
quickest flow of the drug (Patient P in Nemaura, 2014). In this
section, the work only tracked the pro-solvation movement. This
is done by finding the acceleration rate constant corresponding
to convection rate constants for given concentrations in an
individual. The convection rate constant of solution particle
for the patient was estimated by the following model, since it
mimicked the projected concentration curve,
cr(x(t)) =
j
w− l
(e−lt − e−wt) (5)
where t ∈ [0, 24] (Table 3).
The acceleration rate constant of solution particle
corresponding to convection rate constant of solution particle
of a given concentration was defined as the derivative of cr(x(t))
with respect to t (t ∈ (0, 24]), and was thus given by
c′r(x(t)) =
j
w− l
(we−wt − le−lt) (6)
The acceleration was faster in the first few hours (Figure 3) as
evidenced by the acceleration rate constant of solution particle
and which was estimated to be 0.33/h2 in the neighborhood of
TABLE 3 | Parameter estimates in modeling convection rate constants of
solution particle for Equation (5).
Parameters Estimate Std Error t-value Pr(> |t|)
j 0.332908 0.006517 51.08 < 2× 10−16
w 0.340341 0.010495 32.43 < 2× 10−16
l 0.032229 0.001198 26.89 < 2× 10−16
0 declining to −0.01596/h2 after 24 h. The negative acceleration
was projected to be observed after 7 h. It should be noted that
one can also track separate acceleration movements due to anti-
solvation movements that is saturation and/or advection. The
parameters introduced in this section could also be used to
monitor Pharmacodynamic relations where transportation is a
postulated to have an effect in patients.
4. Discussion
The models put forward in this work outlined several
propositions. The energy dependent system transportation and
energy independent system transportation are both involved in
the transportation of the drug efavirenz in the volumetric space.
The transportation attributed to convection can be modeled by
the Ricker’s model. A transportation mode that is independent of
both advection and convection was found and was shown to be
saturable at secondary micro-level transportation.
Using advection rate as the output measure, it was shown that
convection rate of solution particle moves in the same direction
as passive transportation rate of solution particle but is opposite
to the energy dependent system transportation rate of solution
particle. Considering convection rate of solution particle as the
output measure for the primary micro-level transportation, it
was shown that the movement rate is affected negatively by
passive movement rate and positively by energy dependent rate
and advection rate. Furthermore, an analysis of Equation (1)
showed that the principal parameter (advection rate of solution
particle) in modeling transportation can be modeled using the
complementary system to the systemic circulation.
The equation modeling primary micro-level transportation
suggested that for concentrations in the region x < 0.97µg/ml,
passive transportation dominated the energy aided movement.
In this same region, the system is in less control of efavirenz
drug movement suggesting possibilities of ineffective therapy.
The drug can go in and out of the system with relative ease and
was inferred to be controlled mainly by concentration gradient.
FIGURE 3 | The projected plasma concentration of patient P against
the acceleration rate constant of solution particle at different hourly
intervals (time-matched plot) for the duration of the dosing interval of
efavirenz (24 h).
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Moreover, Equation (1) showed that solution particle loses more
movement to passive transportation at very low concentrations.
Marzolini et al. (2001) found that 50% of patients with efavirenz
levels of < 1µg/ml experienced virological failure. However,
other researchers found no association between treatment failure
and efavirenz concentrations below 1µg/ml (Borand et al.,
2014). An experiment that track levels of efavirenz metabolites,
efavirenz plasma concentration, efavirenz concentration at
intracellular level, and the viral loads is required. This is in order
to fully investigate what could potentially be happening so as
to validate the results obtained by models of transportation that
have been developed here. In addition, data on transporters and
metabolizing enzymes associated with efavirenz metabolism and
transportation and patient demographic data is also required.
Other studies have shown concentrations reaching close
to and above 50µg/ml at steady state and investigations of
transportation rate constants of concentrations up to 60µg/ml
were thus considered (Nyakutira et al., 2008; Borand et al.,
2014). Negative advection rate constant of solution particle
reduces convection rate constant of solution particle. The sum
of advection rate constant of solution particle and saturable
rate constant of solution particle gives the convection rate
constant of solution particle. The models gave evidence of
possibility of advection being positive then negative with
increasing concentration in the volumetric space. The maximum
saturable rate constant of solution particle of efavirenz was
found to be 0.7427/h. The secondary micro-level transportation
system was used to infer on the kinetics of dissolution and
solubility of efavirenz relative to concentration in the solution
medium.
At primary micro-level transportation, energy independent
transportation (EI) and convection describe pro-solvation
movements while energy dependent transportation (ED) and
advection are anti-solvation. Furthermore, at secondary level,
the pro-solvation movement is convection while anti-solvation
movement consists of saturation and advection. Additionally,
this work also showed the importance of the mode of
transportation and also concentration in the movement of the
drug in the body and proposes links to solubility. During kinetics
of dissolution phase I, the system supports only a completely
dissolved state. In phase II, the system supports pro and anti-
solvation states, thus we have dissolved and not dissolved
elements of solution particle. However, in phase III the system
no longer supports dissolution.
Dokoumetzidis and Macheras noted that mimicking
simulation of the in-vivo hydrodynamic conditions at experiment
level in attempting to explain dissolution is currently an obstacle
(Dokoumetzidis and Macheras, 2006). However, this work
attempts to give a mathematical description for the dissolution
kinetics of efavirenz. The work tracks kinetic solubility by
describing a solution particle’s inside movement dynamics.
Efavirenz has a small suggested therapeutic index (1−4µg/ml)1.
This region falls in the expected good kinetics dissolution phase.
Furthermore, the patients on efavirenz in the investigated sample
have been classified to be in the good kinetics of dissolution
region.
The investigated case of one patient’s acceleration of
convection, can be extended to the rest of the population in order
to project the transportation behavior in this cohort. However,
full profiles are required to ascertain the results projected here.
This work intuitively looks at transportation in a volumetric
medium with respect to time as compared to the methods
in use to date which track movement with respect to area
and time (Birger et al., 2014). It proposed models for the
transportation modes. Furthermore, the work has found the
existence of possible representation of transportation modes
using mathematical models.
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